Martin Fusek

Speaker

Site Head IT, Roche

After studying electrical engineering Martin Fusek's career started as a project engineer and later as a project manager and quality manager for MES at Propack Data GmbH. In 2005, he moved from the vendor to customer site and hold various IT management positions within Merckle Biotech and later in the Novartis group. In 2019 he took the role of Global Program Manager Manufacturing at Merck KGaA, before he joined Roche in 2021 as Head of Manufacturing IT.

Join Martin Fusek
Book Now!

Sessions

The Great Debate — Traditional vs. Low-Code MES — Which Path Will You Choose?

(1) Challenge Your Peers

Monday, September 22

04:45 pm - 05:45 pm

Live in Berlin

Less Details

What concerns do you have regarding the scalability and long-term viability of low-code MES solutions in your organization?
How do you address potential security and compliance challenges associated with adopting low-code platforms?
What limitations have you noticed in the flexibility of low-code solutions when it comes to specific manufacturing processes?
How do you evaluate the robustness of low-code MES solutions in handling complex manufacturing environments compared to traditional systems?
What challenges have arisen from relying on low-code platforms, particularly in terms of customization and integration with existing systems?
What factors contribute to resistance or hesitation among stakeholders when considering a shift from traditional to low-code MES solutions?

Workshop

Redefining MES with Low-Code and Emerging Technologies

(1) Innovation Café

Tuesday, September 23

11:00 am - 03:00 pm

Live in Berlin

Less Details

What challenges have you encountered with traditional MES solutions, and how might new approaches like low-code platforms help address these issues?
What do you see as the primary benefits of adopting low-code MES solutions over traditional systems?
How do you assess whether a traditional or low-code MES solution aligns better with your organization’s goals and needs?
What are your thoughts on integrating new technologies like cloud computing and SaaS into existing MES environments? How has this affected your operations?
How do you envision the future of MES in your organization, and what role do you think innovative solutions will play in improving manufacturing efficiency?

Workshop

World Café Harvesting Session

Tuesday, September 23

03:30 pm - 04:05 pm

Live in Berlin

Less Details

In the Harvesting Session the workshop moderators of the event will summarize the results of their discussions and highlight key findings from the World Cafés.

Presentation

Company

Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.